Multiple Myeloma Regimen Comparisons

EP: 1.Pharmacists in Multiple Myeloma Care: Essential Roles and Patient Support

EP: 2.Eligibility Factors in Multiple Myeloma Transplant

EP: 3.Multiple Myeloma Care: Pharmacist Team Collaboration

Now Viewing

EP: 4.Multiple Myeloma Regimen Comparisons

EP: 5.Pharmacist's Role in Enhancing Multiple Myeloma Care

EP: 6.Choosing Multiple Myeloma Regimens

EP: 7.Pharmacists' Patient Counseling Role

EP: 8.Advanced Multiple Myeloma Treatments

EP: 9.Pharmacist-Led Care Transitions: Best Practices

EP: 10.Multiple Myeloma Challenges and Treatment Evolution

This is a video synopsis/summary of an Insights involving Gabriel Hinojosa, PharmD, BCOP.

Hinojosa discussed a rare head-to-head study comparing Dara-RVd (daratumumab [Dara], lenalidomide, bortezomib, dexamethasone) and Dara-KRd (carfilzomib, lenalidomide, dexamethasone) in transplant-eligible patients with multiple myeloma. Although initial observations favored Dara-KRd, further analysis revealed no significant difference between the 2 regimens. With both groups showing high overall response rates, the study suggests that Dara-KRd is as effective as Dara-RVd. This insight allows tailoring quadruplet therapy based on patient-specific factors. Shifting focus to patients ineligible for auto-stem cell transplants, Hinojosa highlighted the MAIA trial’s positive outcomes with Dara-RVd, showing a significant progression-free survival benefit and increased likelihood of achieving stringent complete response and measurable residual disease negativity. This prompted the use of triplet therapy for newly diagnosed transplant-ineligible patients, considering the mild adverse effects of subcutaneous daratumumab administration. Overall, these studies contribute valuable data for optimizing multiple myeloma treatment strategies.

This summary was AI-generated and reviewed by Pharmacy Times^® editorial staff.